Cardiogenic Shock in Idiopathic Dilated Cardiomyopathy Patients: Red Flag for Myocardial Decline.

cardiogenic shock dilated cardiomyopathy epidemiology mortality prognosis

Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 Nov 2023
Historique:
received: 23 03 2023
revised: 20 07 2023
accepted: 30 07 2023
pubmed: 10 9 2023
medline: 10 9 2023
entrez: 10 9 2023
Statut: ppublish

Résumé

Idiopathic dilated cardiomyopathy (IDCM) is one of the most common forms of nonischemic cardiomyopathy worldwide, possibly leading to cardiogenic shock (CS). Despite this heavy burden, the outcomes of CS in IDCM are poorly reported. Based on a large registry of unselected CS, our aim was to shed light on the 1-year outcomes after CS in patients with and without IDCM. FRENSHOCK was a prospective registry including 772 patients with CS from 49 centers. The 1-year outcomes (rehospitalizations, mortality, heart transplantation [HTx], ventricular assist devices [VAD]) were analyzed and adjusted on independent predictive factors. Within 772 CS included, 78 occurred in IDCM (10.1%). Patients with IDCM had more frequent history of chronic kidney failure and implantable cardioverter-defibrillator implantation. No difference was found in 1-month all-cause mortality between groups (28.2 vs 25.8%for IDCM and others, respectively; adjusted hazard ratio 1.14 [0.73 to 1.77], p = 0.57). Patients without IDCM were more frequently treated with noninvasive ventilation and intra-aortic balloon pump. At 1 year, IDCM led to higher rates of death or cardiovascular rehospitalizations (adjusted odds ratio 4.77 [95% confidence interval 1.13 to 20.1], p = 0.03) and higher rates of HTx or VAD for patients aged <65 years (adjusted odds ratio 2.68 [1.21 to 5.91], p = 0.02). In conclusion, CS in IDCM is a very common scenario and is associated with a higher rate of 1-year death or cardiovascular rehospitalizations and a more frequent recourse to HTx or VAD for patients aged <65 years, encouraging the consideration of it as a red flag for myocardial decline and urging for a closer follow-up and earlier evaluation for advanced heart failure therapies.

Identifiants

pubmed: 37690150
pii: S0002-9149(23)00719-1
doi: 10.1016/j.amjcard.2023.07.153
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-97

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no competing interests to declare.

Auteurs

Miloud Cherbi (M)

Intensive Cardiac Care Unit, Rangueil University Hospital, Toulouse, France/ Institute of Metabolic and Cardiovascular Diseases, National Institute of Health and Medical Research (Inserm), Toulouse, France. Electronic address: cherbi.miloud@gmail.com.

Edouard Gerbaud (E)

Intensive Cardiac Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut Lévêque, Pessac, France/Bordeaux Cardio-Thoracic Research Centre, Bordeaux University, Pessac, France.

Nicolas Lamblin (N)

Intensive Cardiac Care Unit, CHU Lille, University of Lille, Inserm U1167, Lille, France.

Eric Bonnefoy (E)

Intensive Cardiac Care Unit, Lyon Brom University Hospital, Lyon, France.

Laurent Bonello (L)

Intensive Care Unit, Department of Cardiology, Marseille University Hospital, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France.

Bruno Levy (B)

Intensitve Care Unit, Nancy University Hospital, Vandoeuvre-les Nancy, France.

Julien Ternacle (J)

Intensive Cardiac Care Unit, Cardiology Department, AP-HP, Henri Mondor University Hospital, Créteil, France.

Francis Schneider (F)

Intensive Care Unit, Strasbourg University Hospital, Strasbourg, France.

Meyer Elbaz (M)

Intensive Cardiac Care Unit, Rangueil University Hospital, Toulouse, France/ Institute of Metabolic and Cardiovascular Diseases, National Institute of Health and Medical Research (Inserm), Toulouse, France.

Hadi Khachab (H)

Intensive Cardiac Care Unit, Department of Cardiology, CH d'Aix en Provence, Aix en Provence, France, Avenue des Tamaris Aix-en-Provence Cedex 1, France.

Alexis Paternot (A)

Intensive Care Unit, Hôpital Ambroise-Paré, AP-HP, Paris, France.

Marie-France Seronde (MF)

Cardiology Department, Besançon University Hospital, Besançon, France.

Guillaume Schurtz (G)

Intensive Cardiac Care Unit, CHU Lille, University of Lille, Inserm U1167, Lille, France.

Laurent Leborgne (L)

Cardiology Department, Amiens University Hospital, Amiens, France.

Emmanuelle Filippi (E)

Cardiology Department, Bretagne-Atlantique Hospital, Vannes, France.

Jacques Mansourati (J)

Cardiology Department, Brest University Hospital, Brest, France.

Thibaud Genet (T)

Cardiology Department, Tours University Hospital, Tours, France.

Brahim Harbaoui (B)

Cardiology Department, Lyon University Hospital, University of Lyon, CREATIS UMR5220; Inserm U1044; INSA-15 Lyon, France.

Gérald Vanzetto (G)

Cardiology Department, Grenoble University Hospital, Grenoble, France.

Nicolas Combaret (N)

Department of Cardiology, Clermont-Ferrand University Hospital, CNRS, Clermont Auvergne University, Clermont-Ferrand, France.

Benjamin Marchandot (B)

Cardiovascular Medical-Surgical Activity Center, Strasbourg Uniersity Hospital, Centre Hospitalier Universitaire, Strasbourg, France.

Benoit Lattuca (B)

Department of Cardiology, Nîmes University Hospital, Montpellier University, Nîmes, France.

Guillaume Leurent (G)

Department of Cardiology, Rennes University Hospital, Inserm, LTSI-UMR 1099, Univ Rennes 1, Rennes, France.

Etienne Puymirat (E)

Georges Pompidou European Hospital, Department of Cardiology, Paris, Université de Paris, 75006 Paris, France.

François Roubille (F)

Cardiology Department, Montpellier University Hospital, PhyMedExp, Inserm, CNRS, France.

Clément Delmas (C)

Intensive Cardiac Care Unit, Rangueil University Hospital, Toulouse, France/ Institute of Metabolic and Cardiovascular Diseases, National Institute of Health and Medical Research (Inserm), Toulouse, France; REICATRA, Saint Jacques Institute, Toulouse, France.

Classifications MeSH